circRNA-programmed macrophages enable localized antibody therapy
Abstract
Unlike traditional infectious-disease vaccines, mRNA therapeutics offer a far broader application landscape. Among various next-generation mRNA strategies, protein-replacement therapy is particularly promising.1 Although antibodies are widely used clinically, systemic administration often entails notable systemic adverse effects and treatment burden. By contrast, using mRNA to encode and synthesize antibodies in situ within the body confers multiple advantages: (1) achieving sufficient in vivo expression at lower exogenous doses, thereby increasing effective exposure and bioavailability; (2) a highly modular, rapidly iterable manufacturing process with clear cost and scalability benefits; (3) the ability, via delivery systems, to target specific cells or tissues, improving tissue penetration and local action while reducing off-target effects.
Fields of Study & Subjects
RNA Interference and Gene Delivery
Circular RNAs in diseases
Virus-based gene therapy research
Publication details
- Journal / source
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Volume
- 37
- Issue
- 3
- Pages
- 103010–103010
- Publication date
- 21 July 2026
- Language
- EN